Peer-reviewed veterinary case report
Human intravenous immunoglobulin treatment for dogs with immune low
By Zoia, Andrea et al.·Published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)·2024·San Marco Veterinary Clinic, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective evaluation of the short-term response of human intravenous immunoglobulin therapy in the management of canine immune-mediated thrombocytopenia (2010-2015): 27 cases.
- Species:
- dog
Plain-English summary
A group of 27 dogs with immune-mediated thrombocytopenia (a condition where the immune system attacks platelets) were treated with human intravenous immunoglobulin (hIVIG) and a steroid called methylprednisolone. Within about 60 hours of treatment, 70% of the dogs showed a significant increase in their platelet counts, which is a good sign. All of the dogs that responded to the treatment were alive 14 days later, while those that did not respond had a higher risk of complications. This suggests that hIVIG can be an effective treatment for this serious condition in dogs.
People also search for: dog immune-mediated thrombocytopenia treatment · hIVIG for dogs · dog low platelet count symptoms
Abstract
OBJECTIVE: To describe the short-term response, early prognostic markers, and survival after treatment of canine immune-mediated thrombocytopenia (ITP) with human intravenous immunoglobulin (hIVIG) and methylprednisolone. DESIGN: Retrospective cohort study. SETTINGS: Private referral veterinary medical center. ANIMALS: Twenty-seven client-owned dogs with primary or secondary ITP. INTERVENTIONS: All dogs received 2 mg/kg IV methylprednisolone once daily and a single infusion of 5% hIVIG administered over 6-12 hours. MEASUREMENTS AND MAIN RESULTS: A substantial increase in platelet count within 60 ± 12 hours post-hIVIG infusion (T) was observed in 19 of the 27 (70%) dogs with ITP (responders). Thirty-four variables, including serum immunoglobulin (Ig) G concentration 24 ± 12 hours post-hIVIG infusion (TIgG) and increase in serum IgG concentration 24 ± 12 hours post-hIVIG infusion (TΔ), were compared between responders and nonresponders at 5 different time points. Mortality rates of responders and nonresponders were evaluated 14 days post-hIVIG infusion. Serum TIgG and serum TΔwere both significantly higher at Tin responders. All responders were alive 14 days post-hIVIG infusion, and their mortality rate was significantly lower compared with nonresponders. CONCLUSIONS: Responder dogs had an excellent 14-day survival rate. Serum TIgG and serum TΔconcentrations accurately predicted response status at 60 hours post-hIVIG infusion.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39037266/